



## FROM THE DESK OF MD/ED

Our Valued Investors and Stakeholders,

We are finally seeing the green shoots of economic recovery growing around us. The global economy is slowly, but surely, stabilising. In this issue of the monthly PEG newsletter, we will review the new norms of investing, as well as the economic state of the country and the race for the pandemic cure.

Due to COVID-19, the world has experienced extended low interest rates and increased liquidity in the market. Reflecting on the current trend, companies are emphasising on the need for Environment, Social, and Corporate Governance (ESG) solutions in their investments. At PEG, we want to ensure our investors of our dedication to identify projects that incorporate our ESG strategies and continue to support sustainability.

Under the new norm, more and more people are spending time online, particularly on services and content compared to physical brick and mortar stores. Most events are now hosted virtually, through various video conferencing platforms and social media. We have to be prepared to pivot and meet the consumers where they are most comfortable.

Lastly, while pharmaceutical companies are vying to be the first one to have their vaccine in the market, we do not leave out all the other companies in the supply chain who will have an important role to play in the distribution of the cure. In this newsletter, we learn about an Italian company that specialises in glass vials that will one day be filled with the COVID-19 vaccine.

Stay safe and healthy.



Group COO of Potential Excelerate Group  
 Dato' CK Cheong

## CONTENT

### 01 From the Desk of MD/ED

### 02 Corporate News Flash

- Sustainable ESG investing is set to surge in the wake of the coronavirus pandemic
- Malaysians have spent less and invested more during the MCO
- Malaysia's record Q2 GDP plunge looks grim but worst is likely over, say economists
- Beneficiaries of the Pandemic: Separating the wheat from the chaff
- The COVID vaccine will require billions of tiny glass vials – and this Italian billionaire family is making them

### 09 Investor Update

- WOBB Sdn. Bhd

### 10 Corporate Media Coverage

- PEG Recognised By Malaysia's Ex-Police Association

*"If it doesn't challenge you, it doesn't change you."*

*Fred DeVito*

# CORPORATE NEWS FLASH

## 1 (i) Sustainable ESG investing is set to surge in the wake of the coronavirus pandemic

(Source: CNBC, June 2020)

### Sustainable funds see record inflows in first quarter



SOURCE: Morningstar Direct, as of 3/31/2020. (ESG Integration, Impact, and Sustainable Sector funds as defined in Sustainable Funds U.S. Landscape Report, 2018. Includes liquidated funds; does not include funds of funds.)

THE coronavirus pandemic has altered society in immeasurable ways, including, of course, investing. Stocks that benefited from people staying home, such as Netflix and Zoom Video, outperformed expectations in the past few months, while retailers and airline companies, among others, saw their stocks fall off a cliff. And now some of those worst-performing stocks of March and April are staging a comeback, as economies begin to reopen.

But there could be a more long-lasting effect on Wall Street: COVID-19 may well prove to be a major turning point for ESG investing as the pandemic alters society's values.

This investing approach, which evaluates a company's environmental, social and governance ratings alongside traditional financial metrics, was already coming off a banner year, and its reach continues to expand. So far this year, U.S.-listed sustainable funds are seeing record inflows, despite the market turmoil.

### Asset managers with largest sustainable fund flows in Q1


Manager	Number of funds	Total Flows
iShares	15	\$6.3B
Vanguard	4	\$1.1B
Calvert	28	\$1.1B
Dimensional	4	\$0.8B
TIAA/Nuveen	17	\$0.6B

SOURCE: Morningstar Direct

"We expect increased investor focus on ESG considerations after COVID-19, with particular demand for greater corporate transparency and stakeholder accountability," UBS said in a recent note to clients. "The crisis underscores the relevance of ESG considerations to company performance

and investment returns, and we expect that this will continue to influence corporate and investor actions going forward," the firm added.

### Investors favor passive sustainable funds



SOURCE: Morningstar Direct

### COVID-19 'accelerating' ESG investing

Before the pandemic, stakeholder capitalism — the idea that companies' sole focus shouldn't be deepening shareholder pockets — was growing in popularity. And the pandemic will likely accelerate this shift, with investors rewarding companies that responded to the crisis by focusing on long-term goals, rather than prioritizing near-term profit at all costs.

"This global pandemic has really put in pretty sharp relief the importance of how corporations treat their stakeholders, in particular their employees and their customers," said Hale. "So much of even corporate value these days is based on intangible assets like your reputation, and I think stakeholders will remember how companies either rose to the occasion or failed to rise to the occasion during the pandemic and that will pay off for them down the line."

Andy Howard, head of sustainable research at Schroders Investment Management, added that COVID-19 will likely spark increased interest in trends that have been building, such as employee protection. Since March more than 40 million people have filed for unemployment protection in the U.S., with minority workers typically faring worse. "That's not a new trend; we've been talking about it for a while," said Howard. "But effectively the coronavirus crisis is starting to crystalize some political actions trying to accelerate the reversal of some of those trends."



Read more at

Read more at: <https://www.cnbc.com/2020/06/07/sustainable-investing-is-set-to-surge-in-the-wake-of-the-coronavirus-pandemic.html>

## Our Research Team View

*The COVID-19 crisis has not only brought on the greatest recession since World War II, but investors are also calling it the 21st century's first "sustainability" crisis. It has renewed the focus on climate change, acting as a wake-up call for decision makers to prioritise a more sustainable approach to investment.*

*Pandemics and environmental risks are comparable in terms of impact. The effects of the COVID-19 crisis on the real economy and the financial system highlight the limits of most forecasting models, which are not meant to take account of non-linear, complex systemic risks. In terms of asset classes, equity continues to dominate and represents around half of the total ESG assets under managements (AUMs). The green bond market is burgeoning, and sustainability is quickly spreading to other asset classes.*

*We look forward to the continued emphasis on stakeholder capitalism and are proud to have instilled such a mindset in our company.*

## 1 (ii) Malaysians have spent less and invested more during the MCO

(Source: The Edge Markets, July 2020)

WHILE Malaysians spent less during the Movement Control Order (MCO) period, they still participated in the stock market and put their money to work in various financial instruments, according to a recent survey conducted by Personal Wealth.

### Key findings from the survey:

- 82.4% of the respondents had put money aside to invest during the MCO period
- 13.6% invested in exchange-traded funds (ETFs) via robo-advisors
- 6.2% invested directly in ETFs
- 5.3% put their money in peer-to-peer financing platforms and 3.1% bought cryptocurrencies.
- 69.8% spent less during the MCO, while 18.3% spent more
- 60.9% spent more on food and beverage during the MCO period
- 26.2% spent more on healthcare products and services
- 80% of the respondents said they already had emergency savings prior to the start of the MCO
- ~78.6% of the respondents would be increasing their allocation to their emergency savings fund in the future
- 69.8% would save more while 54.7% said they would invest more

Personal Wealth's "Spending habits during the MCO" survey ran from June 11 to 19. There were 619 Malaysian respondents with various income levels. Most of them belonged to the following age groups: 25 to 34 (42.8%), 35 to 44 (29.4%) and 45 to 54 (12.4%).

## Our Research Team View

*COVID-19 has changed almost every aspect of our daily lives, and consumer spending is no exception. Due to the lock-in measures, there were limited options to go shopping or have gatherings the pre-pandemic way.*

*Consumption behaviours have undoubtedly shifted, favouring digital and online sales and services. Even in the stock market, it is clear how the tech-savvy stocks have appreciated dramatically, compared to non-tech stocks.*

*As the article pointed out, many consumers find themselves spending less and spending differently. Instead of eating out at a restaurant, people are calling for food delivery. More people are saving and investing more, with a majority of respondents planning to cultivate healthy financial habits.*

*There is also an increased focus on spending time wisely, more with family at home and less on social activities. The pandemic has realigned our priorities and allowed us to carefully examine our financial planning.*




Read more at

<https://www.theedgemarkets.com/article/the-wall-survey-malaysians-have-spent-less-and-invested-more-during-mco>

# CORPORATE NEWS FLASH

## 1 (iii) Malaysia's record Q2 GDP plunge looks grim but worst is likely over, say economists

(Source: Malaysian Department of Statistics and Malay Mail, August 2020)



still performed reasonably well when this was considered.

Economic growth from April to June contracted 17.1 per cent, Bank Negara Malaysia announced last week, as domestic spending and exports fell to levels not seen since the 1997 Asian Financial Crisis.

Bank Negara Malaysia Governor Datuk Nor Shamsiah Mohd Yunus said the record low growth numbers stemmed from the movement control order enforced on March 18 that spanned close to three months, as public health authorities attempted to curb the spread of COVID-19 that peaked in April.

Growth contracted by 20 per cent in April but improved slightly in May and June to -17 and -15 per cent, respectively, after the government slowly lifted its movement control order and allowed most key economic sectors to resume, Barjoi noted.

"So on average in the three months it contracted at around 17.1 per cent," he said.


### Decent performer

Malaysia shut its borders and imposed strict movement restrictions far earlier compared to most of its South-east Asian neighbours like Indonesia, Thailand and Singapore, which only enforced tighter travel curbs beginning April to early May.

Singapore became one of Asia's worst Q2 economic performers to date, contracting by 42.9 per cent compared to the previous quarter to place the country under a technical recession.

The island republic's latest GDP estimate — computed largely from data in April and May — was worse than analysts' forecast, CNBC reported.

Economists polled by Reuters had expected the South-east Asian economy to shrink by 37.4 per cent quarter-over-quarter.



ECONOMISTS pinned the country's worst-ever second quarter GDP contraction on Putrajaya's imposition of movement control ahead of regional rivals and said Malaysia

Thailand's Q2 growth contracted by 12.2 per cent, the largest in 22 years while Indonesia's 5.32 per cent contraction also beat most economists' estimates.

"As a matter of fact we did quite well considering we are already showing signs of recovering," he added.



Read more at

<https://www.malaymail.com/news/malaysia/2020/08/26/malaysia-record-q2-gdp-plunge-looks-grim-but-word-is-likely-over-say-econ/1897145> and on the Malaysian Department of Statistics' website.

## Our Research Team View

*While the Movement Control Order negatively impacted the economy, it allowed the country to minimise the health risks of its citizens. With the lifting of most restrictions, business activities have shown signs of improvement.*

*Experiencing daily traffic jams, packed malls over the weekend, and long queues at your favourite restaurants have brought back a sense of normalcy. Regardless, the threat of another wave of the coronavirus is still present and the need to adhere to the standard operating procedures is vital to the health of the economy.*

*For the September Monetary Policy Committee (MPC) meeting, economists have argued both ways – some predicting that the OPR will be further reduced, while others the opposite. As the loan repayment moratorium is set to end this month, the MPC must carefully consider the effects of changing the interest rate. With the global economy stabilising, it may be best to keep the rates as it. Comparatively, Malaysia still offers a better yield than the US, UK, EU, and Japan.*

*The recovery is here, and we applaud Bank Negara of Malaysia for its effective strategy to stimulate the economy. With careful inflation control, we have seen the ringgit appreciate and with the prudent monetary tools, we see the potential for the economy to show resurgence with positive growth by the end of the year.*


## 1 (iv) Beneficiaries of the Pandemic: Separating the wheat from the chaff

(The Edge Markets, August 2020 and Bursa Malaysia, September 2020)

SINCE the COVID-19 pandemic began, dozens of companies have announced ventures into the manufacture of gloves, test kits, personal protective equipment (PPE), vaccines and ventilators. It begs the question, however, of whether their forays into the healthcare segment will succeed, as some do not have the relevant experience and know-how. Still, their share prices have surged to stratospheric levels on the back of the COVID-19 theme and ample market liquidity. This is despite a lack of concrete execution plans, with some having only signed a memorandum of understanding. We take a look at the winners and potential beneficiaries of the pandemic, and the value that has been added to these counters since March 11, when the World Health Organization declared COVID-19 a global pandemic.


### Pharmaniaga Bhd.

Market Cap: RM1.469 bil (as at 1st Sept 2020)



### Duopharma BioTech Bhd.

Market Cap: RM2.577 bil (as at 1st Sept 2020)




Interest in Pharmaniaga and Duopharma had been driven by developments surrounding the formulation and distribution of a vaccine for COVID-19, as the two counters have been tapped by the government to package the vaccine for use in Malaysia once available.

Science, Technology and Innovation Minister Khairy Jamaluddin later clarified, however, that the selection of companies would not be limited to the two companies.

# CORPORATE NEWS FLASH

## Solution Group Bhd

Market Cap: RM210.3 mil



The company is finalising a collaborative agreement with China’s vaccine specialist CanSino Biologics. The parties signed a MoU on Aug3.

Under the deal, Solution Group will undertake the fill and finish process for a COVID-19 vaccine supplied by CanSino, The potential vaccine, which is in Phase 3 trials, is being co-developed by CanSino and the Beijing Institute of Biotechnology in the Academy of Military Medical Science.

CanSino is listed in Hong Kong and undertook its secondary listing in Shanghai on Aug 13. The Tian-jin- based pharmaceutical producer’s share price nearly doubled on the Star Market debut.

## Ho Wah Genting Bhd

Market Cap: RM557.5 mil (as at 1st Sept 2020)




In the past few months, Ho Wah Genting (HWGB), which makes wires, cables and power supply cords, has made a slew of announcements regarding ventures into the provision of essential medical and health-care products ranging from diagnostic kits to clinical trials for vaccines. In its latest filing on Aug 6, the company said its unit HWGB Biotech had partnered with US-based E-MO Biology Inc (EBI) to invest US\$1 million (RM4.2 million) in EBI for a profit entitlement of 40% from the commercialised vaccine.

HWGB will have exclusive rights to the production, distribution and sale of the repurposed vaccine based on the polio vaccine for use in preventing COVID-19 infections in Southeast Asian countries.

## Bintai Kinden Corp Bhd

Market Cap: RM198.6 mil (as at 1st Sept 2020)



Mechanical and electrical engineering works specialist Bintai Kinden said on Aug 14 that it was venturing into developing a vaccine for COVID-19 through a partnership with a US pharmaceutical company.

A MoU with vaccine research firm Nugenerex Immuno-Oncology (Generex) was inked to fund and manage a synthetic peptide vaccine for COVID-19.

Generex is involved in robust research and development in creating on-demand peptide vaccines to control pandemic viruses. It has developed its proprietary, patented li-Key immune system activation technology that holds promise for stopping viral outbreaks such as the current pandemic.

### Our Research Team View

*Within the past month, we have seen steady flows of positive drug trial results and regulatory approvals for the COVID-19 vaccine. These news are always good signs for the pharmaceutical stocks.*

*In this article, we have only listed a few of the local companies involved with the highly anticipated pandemic cure. Everyone seems to want a piece of the lucrative vaccine-related-pharmaceutical pie.*

*Taking note of the spillover effects, companies participating in the fill and finish process and distribution process have drawn considerable interest from the market. There seems to be a euphoria surrounding the rubber glove and pharmaceutical stakes that is spreading to include cold-chain logistics companies. Investors are scrambling to find the next big thing that would benefit from a vaccine breakthrough.*

*In the next article, we explore the background of one of the key players in Italy who is involved with the packaging of the vaccine.*



Read more at <https://www.theedgemarkets.com/article/beneficiaries-pandemic-separating-wheat-chaff>

## CORPORATE NEWS FLASH

# 1 (v) The COVID vaccine will require billions of tiny glass vials – and this Italian billionaire family is making them

(Source: Forbes, September 2020)



At the height of Italy's lockdown in April factories were shuttered across the country. But in Piombino Dese, a small town about 20 miles outside of Venice, the hulking glass-cutting machines at the Stevanato Group kept whirring along, spitting out millions of ampoules and syringes. Hundreds of employees donned face masks to work around the clock in three daily shifts, seven days a week – making everything from insulin pen cartridges to miniature glass barrels and – most pressingly – millions of tiny sterile vials, each one smaller than a single fluid ounce, that one day will house doses of a COVID-19 vaccine.

“Every Saturday and Sunday, even on Easter, I went to work alongside my employees to show that we were in the trenches as well,” says Franco Stevanato, the 46-year-old CEO of the group and grandson of its founder, Giovanni.

Vaccines, like most injectable drugs, need to be packaged in sterile glass. Glass is essentially impermeable to corrupting gases like oxygen while even high-grade plastic lets some air inside. Making these vials was a big business even before COVID-19 appeared in January. Last year, the global pharmaceutical industry purchased some 12 billion vials. The Stevanato Group, a 71-year-old family-owned firm, provided more than 2 billion of those (The company is also the world's largest manufacturer of cartridges for insulin pens). A COVID-19 vaccine, which likely will have to be administered in two separate injections, will require billions of additional vials. Stevanato expects the pandemic to drive up demand for its glass vials by 20% over the next two years.

“We proactively started to supply our customers with everything they wanted [to fight] COVID-19,” says Franco. “There was no magic strategy. We tried to move quickly and took enormous risks by anticipating some investments, because it was the right time to do it.”

Other than making the actual glass, which they buy from big outfits like Corning and Schott, Stevanato does it all. They design the vials. They make the machines that craft and sterilize the containers. They work with medical regulators in 150 different markets around the world. And then many of their customers use Stevanato-made machines to package the drugs before shipping them to pharmacies and hospitals.

Those machines are a key differentiator. In 2007, when French pharma giant Sanofi needed a supply of sterile syringes that could quickly hit the market, Stevanato developed a ready-to-use syringe that didn't require any additional sterilization. Stevanato built its own machines to wash and sterilize the syringes and patented the

whole process, creating a product line that is now one of the company's top earners.

“They really value quality and they really value customers and connecting the customer needs to their products,” says Ron Verkleeren, who manages the life sciences division at Corning and has worked with Stevanato since 2011. “That really sets them apart from the competition.” It's a solid, if unspectacular, business. In 2019, Stevanato netted \$47 million on \$675 million sales. Forbes estimates that Sergio Stevanato, the 77-year old company president and son of the founder, owns a 68% stake worth \$1.8 billion. Sergio's sons, Franco (the CEO) and Marco, the 47-year-old vice chairman, run the place now. Each own 16%, worth more than \$400 million apiece.

Big changes are afoot. In June, the group raised \$59 million in a private debt placement, the first time the company had ever sought outside funding. They plan to use the money to develop wearable medical devices and machines to automatically assemble them. And the family has plans to take the company public within the next three years.

“The banks we're working with want us to go public earlier, but I want to do it when I feel sure, regardless of COVID-19,” says Franco.

Stevanato has been ramping up for a COVID-19 vaccine for months. The firm hired more than 580 new workers in the first six months of 2020. In late June, Stevanato signed a deal with Norway's Coalition for Epidemic Preparedness and Innovations (CEPI), a Gates Foundation-backed group that is assisting with scaling nine different COVID-19 vaccine projects — including efforts by Boston-based biotech Moderna and Oxford University — to supply 100 million borosilicate glass vials for up to 2 billion doses of vaccine.

Borosilicate glass can withstand much higher temperatures than other types of glass and is more resistant to external chemicals, making it the glass of choice for sensitive medicines like vaccines. Stevanato is also supplying several other significant vaccine efforts it can't currently disclose, along with 30 more in early stages of development. Altogether, that's more than a fifth of the 176 vaccines in the works around the world.

“We talked with every glass producer and the Stevanato

## CORPORATE NEWS FLASH

Group was the only group that still had uncommitted glass [vial production] capacity,” says Jim Robinson, deputy chair of CEPI’s scientific advisory committee. “They had the prize that everyone wanted.”

Vaccines face much tougher regulatory barriers than most other medicines and need to be stored in sterile glass vials and syringes, says Verkleeren of Corning. “A lot of drugs degrade in the presence of oxygen. It would take millions of years for one molecule of oxygen to permeate glass, and it would take minutes for it to go through plastic,” he says. “Quality and sterility are really, really important, because if it’s not sterile, or there’s a quality problem, and you’re injecting something into the body, it can be very, very serious.”

The Stevanato Group was founded on the outskirts of Venice, a city with a long tradition of glassblowing, in 1949 to make bottles for wine and perfume. The firm, originally called Soffieria Stella, grew as the postwar Italian economy boomed. By 1959, they needed more space, so they relocated to Piombino Dese, an industrial town situated on the confluence of five rivers.

As food producers began to switch to plastic in the 1960s, Giovanni Stevanato took a risk and doubled down on glass, developing a machine capable of rapidly producing containers from glass tubing at scale. The 3BS machine, named after Stevanato and his three co-inventors — Bormioli, Bottaro and Bardelli — enabled the firm to double production and target a new market: the growing pharmaceutical industry. In the early 1970s, the family shut down Soffieria Stella entirely, cementing its pivot to medical glass packaging.

“The first decades were very difficult,” says Franco, particularly because the family shunned outside investment. But they made headway. “By making our own machines, we could produce 50% to 60% more than our competitors. Because my father reinvested all our profits into the company, we could advance our technology faster than the others. [They] would buy their technology in Germany, but we could double their production with the same number of employees.”

Franco and Marco entered the family business in 1998 in their mid-twenties, two years after the death of Giovanni. The first order of business: rebuffing a series of acquisition offers from larger competitors. The second order: Expanding the company abroad. In 2008, the family opened its first overseas plant — in Monterrey, Mexico — to target the North American market. Stevanato now has

a network of 12 factories on four continents. In 2016 the group entered the U.S. for the first time, via its acquisition of German plastic packaging firm Balda for \$112 million, which has two facilities in southern California.

One advantage of providing complex, specially designed packages is that they are patented and included in the regulatory approval process for new drugs, meaning that pharmaceutical firms must use the company’s packaging for the duration of the product’s lifespan. According to Aaron DeGagne, healthcare analyst at Morningstar, this effectively locks in business for decades, because drug producers often continue to use the same packaging—even after the medicine’s patent expires and it becomes a generic drug.

Spinning a sleek, Stevanato-made insulin pen between his fingers during an interview via video, Franco spells out a future in which his family firm expands into more complex products. “Now we have [insulin] pens, and tomorrow the devices will be more self-medicating, analyzing...and much more evolved,” he explains. For example, a cancer patient may be able to self-administer drug infusions at home. “This is the big challenge we want to dive into over the next 10 to 20 years.”



Read more at

<https://www.forbes.com/sites/gaomtdagene/2020/09/03/the-covid-vaccine-will-require-billions-of-fragile-glass-vials--and-the-dales-biformire-family-is-making-them/#12ad044440>

### Our Research Team View

*With the competitive race to create the COVID-19 vaccine, many pharmaceutical companies are moving into or are already in the final stage of clinical trials. As the world waits impatiently for the cure to arrive, companies and governments have already been making arrangements for the fill and finish and distribution processes to be completed.*

*Growing from a company crafting specialty bottles for perfume and wine, the Stevanato Group has perfectly positioned itself to profit from packaging vaccines that will save countless number of lives. When the vaccine is ready, the Group will have an important role to play.*

*The experts believe that a vaccine is likely to become widely available by mid-2021, which would be a scientific feat. Typically, a vaccine would take years, if not decades, to develop.*

*Russia’s Sputnik V is on its way to be registered as the first vaccine against COVID-19. China is expecting to have a vaccine ready for the general public by end of the year. While we are excited for the cure, we rely heavily on the health regulators to ensure the safety of these vaccines.*



## Our Portfolio companies

# WOBB

WOBB Sdn. Bhd.

**Business:**  
Recruitment Platform

**Country:**  
Malaysia

Read more at  
<https://my.wobbjobs.com/>

WOBB's CEO, Mr. Derek Toh, was featured on Digital News Asia's Digerati50 for 2020-2021. Digerati50 highlights 50 individuals who will help to shape Malaysia's Digital Economy. With the increasing number of applicants searching and applying for jobs online, there is not much focus on clearly defining the work environment and culture to ensure a good match for both the applicant and company.

This is where WOBB is different – WOBB is on a mission to humanise digital recruitment. By enabling applicants to submit a video cover letter or experience the work environment through a visual walk-through of the company's office, WOBB wants to match the applicants' personalities with companies that will complement them and allow them to grow. By doing so, both the companies and applicants benefit with healthy and strong relationships.

Amid the Movement Control Order, WOBB has recently moved into a new location for its headquarters. During our most recent investor update meeting, we were given a tour of its new facility. The layout tells an interesting story about WOBB's milestones and values and also provides a spacious environment for the various events it intends to hold.

Despite the pandemic, which has caused many companies to freeze their hiring, WOBB has managed its operations and is seeing its number of active jobs and revenue recover to amounts it is familiar with. WOBB believes that it will outperform its Q3FY2020 revenue projections.

## Company Updates



WOBB has been actively helping its corporate clients like Lazada, AIA, Digi, and MDEX to conduct online career fairs. With its new subscription model, WOBB has seen a strong adoption rate. It now makes up majority of WOBB's total revenue.



# Potential Excelerate Group (PEG) Recognised By Malaysia's Ex-Police Association




Potential Excelerate Group had contributed greatly to the Malaysian Ex-Police Association's welfare fund, which will provide support to former police officers and their family members who are suffering from disability and chronic diseases or affected by disasters or accidents.

The fund can also be used to help former officers who need financial assistance for their children's education. Additionally, the donation will help the association to construct a new building in the state of Selangor.

On August 17, 2020, Dato' CK Cheong, COO of PEG, received a certificate and a token of appreciation from the Malaysian Ex-Police Association on behalf of the Group. The former police officers graciously stopped by our office to show their appreciation.



On September 9, 2020, Dato' Sri Sherwin Chew, CEO of PEG presented the mock cheque to the Association at their High Tea event.



### Disclaimer

While our Research Team has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of the information presented herein. The information provided is for general understanding and knowledge only to restricted recipients. Nothing presented herein is intended to constitute any investment advice and you should consult your financial advisor before making any investment decisions.

### Editorial

- Strategy | Steven Liew
- Corporate Finance | Albert Ting     Jayden Sho
- Corporate Communication | Adrian Cheng
- Marketing | Miyuki Chia
- Customer Service | Angel Phoon
- Editor | Alanis Chew
- Graphic Designer | Jennifer Tee

Feedback Enquiries please email to [info@peggroup.com](mailto:info@peggroup.com)